New biomarker may predict response to PD-1 for melanoma; Academic team offers new tech for 'fixing' proteins;

> Investigators at the Mayo Clinic have flagged a new protein marker that may be predictive for patient response to PD-1 blockade immunotherapy for melanoma. An abstract of their findings was presented today at the American Association for Cancer Research International Cancer Immunotherapy Conference in New York City. Release

>  Researchers from Northwestern University and Yale University say they have developed a "user-friendly" technology that can help scientists fix "broken" proteins--a field that could have broad therapeutic implications. Release

> Three new studies flag metabotropic glutamate receptor 2 (mGluR2) as a new molecular target for the treatment of addiction. Release